Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).

NCT01761786 is registered in ClinicalTrials.gov with Vera HM Deneer as lead sponsor.

NCT NCT01761786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01761786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).
Lead sponsor
Vera HM Deneer
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2011
Completion date
April 4, 2019
Enrollment
2,700 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction, stemi